A composition for ameliorating, preventing, and / or treating muscular dystrophy, multiple sclerosis, and / or related diseases.

Aureobasidium pullulans-derived beta-glucan addresses the limitations of current treatments for muscular dystrophy by reducing inflammation and fibrosis, enhancing dystrophin expression and muscle strength in Duchenne muscular dystrophy patients.

JP2024545484APending Publication Date: 2024-12-09SOPHY INC +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023579638
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-03-17
Filing Date
2022-11-07
Publication Date
2024-12-09

AI Technical Summary

Technical Problem

Current treatments for muscular dystrophy, such as corticosteroids, have significant side effects and do not effectively modulate inflammation and fibrosis, leading to progressive muscle weakness and early death in patients.

Method used

A composition containing beta-glucan produced by Aureobasidium pullulans strain N-163, which modulates the immune system and gut microbiota to reduce inflammation and fibrosis, improving muscle function and dystrophin expression.

Benefits of technology

The beta-glucan composition significantly reduces inflammatory markers like IL-6 and TGF-β, increases dystrophin levels by 32.8%, and improves muscle strength in Duchenne muscular dystrophy patients, demonstrating potential as a safe and effective disease-modifying treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545484000001_ABST
    Figure 2024545484000001_ABST
Patent Text Reader

Abstract

The present invention provides beta-glucans, compositions comprising the beta-glucans, and methods of using the beta-glucans to ameliorate, prevent, and / or treat muscular dystrophies.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims the benefit of the filing date of Japanese Application No. 2021-200800, filed on December 10, 2021, entitled "A composition for improving, preventing and / or treating muscular dystrophy, multiple sclerosis and / or related diseases," and Japanese Application No. 2022-42559, filed on March 17, 2022, entitled "A composition for improving, preventing and / or treating muscular dystrophy, multiple sclerosis and / or related diseases," the contents of which are incorporated by reference in their entireties into this specification.

[0002] The disease-modifying immunomodulatory effects of 1,3-1,6 beta-glucan produced by the N-163 strain of Aureobasidium pullulans in young boys with Duchenne muscular dystrophy are presented with the results of an open-label, prospective, randomized, comparative, multicenter clinical study.

[0003] The present invention relates to beta-glucan for ameliorating, preventing and / or treating muscular dystrophy, multiple sclerosis and / or related diseases. The present invention also relates to compositions comprising beta-glucan for ameliorating, preventing and / or treating muscular dystrophy, multiple sclerosis and / or related diseases, and methods of using beta-glucan for ameliorating, preventing and / or treating muscular dystrophy, multiple sclerosis and / or related diseases. [Background technology]

[0004] Introduction: Duchenne muscular dystrophy (DMD) is a devastating X-linked neuromuscular disorder that results in severe and progressive skeletal muscle weakness, leading to lameness and premature death with concomitant defects in cardiac and respiratory muscles. Mutations in the dystrophin gene that result in complete loss of dystrophin protein [2] remain the primary underlying mechanism. Loss of dystrophin leads to damage to the plasma membrane of muscle fibers, distorting the structural stability of the plasma and leading to muscle fiber weakness. Weakened muscle fibers cannot withstand the cycles of contraction and relaxation that occur during muscle function. Damage to the membrane releases cytoplasmic contents, triggering the immune system, leading to further muscle fiber damage, weakness, and ultimately death [3]. Neutrophil infiltration and macrophage phagocytosis of degenerated tissue [3] perpetuates a chronic pro-inflammatory state, preventing the repair of muscle damage that would otherwise occur in a highly coordinated manner to be repaired more quickly under other physiological conditions. Muscles are relatively immunologically privileged, with a low capacity to generate local immune responses and a low rate of abscess and granuloma formation [3]. Therefore, modulating inflammation and immunity to reverse the chronic inflammatory state is essential in therapeutic approaches to DMD. Steroid therapy is the most commonly used approach for immunomodulatory treatment. However, side effects include weight gain, bone weakening, hypertension, and behavioral changes, in addition to muscle weakness and atrophy over time, which contribute to disease exacerbation [4,5]. Therefore, strategies to support immune modulation with fewer side effects need to be developed. Nutritional supplements are a potential option. Besides beta-glucan producing motor improvement in a zebrafish model of DMD [6], 1,3-1,6 beta-glucan from the black yeast Aureobasidium pullulans N-163 strain has been reported to attenuate inflammation, as evidenced by the reduction of anti-inflammatory markers such as CD11b, serum ferritin, galectin-3, and fibrinogen. It also produces beneficial immunomodulation via a decrease in the neutrophil-to-lymphocyte ratio (NLR) and an increase in the lymphocyte-to-CRP ratio (LCR) and leukocyte-to-CRP ratio (LeCR) in healthy human volunteers [7].Attenuation of the inflammatory cascade associated with lipotoxicity in a mouse study has also been reported.[8] Another study conducted in an animal model of nonalcoholic steatohepatitis (NASH) showed a reduction in liver inflammation and accumulation of F4 / 80+ cells (macrophages associated with inflammation) in the liver.[9] This pilot study evaluated the immunomodulatory effects of beta-1,3-1,6 glucan produced by A. pullulans strain N-163 compared with conventional treatment regimens in patients with DMD. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] US20090022799A1 [Non-patent literature]

[0006] [Non-Patent Document 1] Ikewaki N, Kurosawa G, Iwasaki M, Preethy S, Dedeepiya VD, Vaddi S, Senthilkumar R, Levy GA, Abraham SJK. Hepatoprotective effects of Aureobasidium pullulans derived Beta 1,3-1,6 biological response modifier glucans in a STAM- animal model of non-alcoholic steatohepatitis. Journal of Clinical and Experimental Hepatology-2022. https: / / doi.org / 10.1016 / j.jceh.2022.06.008 [Non-Patent Document 2] Preethy S, Ikewaki N, Levy GA, Raghavan K, Dedeepiya VD, Yamamoto N, Srinivasan S, Ranganathan N, Iwasaki M, Senthilkumar R, Abraham SJK. Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential for applications in human health and disease. BMJ Open Gastroenterology 2022;9:e000985. doi: 10.1136 / bmjgast-2022-000985 [Non-Patent Document 3] Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Subramanian S, Ikewaki N, Iwasaki M, Senthilkumar R, Preethy S, Abraham S. Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, randomized, comparative clinical study. medRxiv 2021.12.13.21267706; doi: 10.1101 / 2021.12.13.21267706 [Non-Patent Document 4] Vetvicka V, Vetvickova J. Combination Therapy with Glucan and Coenzyme Q10 in Murine Experimental Autoimmune Disease and Cancer. Anticancer Res. 2018 Jun;38(6):3291-3297. doi: 10.21873 / anticanres. Summary of the Invention

[0007] The present invention relates to the following: (1) A composition for ameliorating, preventing, and / or treating muscular dystrophy and / or multiple sclerosis, comprising beta-glucan. (2) The composition described in (1), wherein the beta-glucan comprises beta-glucan produced by Aureobasidium pullulans N-163 (NITE P-03377). (3) The composition according to (1) or (2), which is used for improving, preventing, and / or treating Duchenne muscular dystrophy. [Brief description of the drawings]

[0008] [Figure 1] Figure 1: CONSORT flow diagram of the study. [Diagram 2] Figure 2: IL-6 showed the most significant decrease in the N-163 steroid-ve group compared to the other groups (*significance of p-value <0.05). [Diagram 3] FIG. 3: IL-13 levels showed a statistically significant increase in the control group and a decrease in the treatment groups (*significance of p-value<0.05). [Figure 4] Figure 4: The levels of TGF-β showed a significant decrease in the N-163 steroid-ve group compared to the other groups (*significance of p-value <0.05). [Diagram 5]Figure 5: Dystrophin levels showed a significant increase in the N-163 steroid-ve group compared to other groups (*significance of p-value < 0.05). [Figure 6A] Figure 6: Levels of A. haptoglobin; B. CK, and C. urinary myoglobin in different groups in this study (*significance of p-value <0.05). [Figure 6B] Figure 6: Levels of A. haptoglobin; B. CK, and C. urinary myoglobin in different groups in this study (*significance of p-value <0.05). [Figure 6C] Figure 6: Levels of A. haptoglobin; B. CK, and C. urinary myoglobin in different groups in this study (*significance of p-value <0.05). [Figure 7A] Figure 7: Levels of A. titin, B. TNF-α, and C. cystatin C in different groups in this study (*significance of p value < 0.05). [Figure 7B] Figure 7: Levels of A. titin, B. TNF-α, and C. cystatin C in different groups in this study (*significance of p value < 0.05). [Figure 7C] Figure 7: Levels of A. titin, B. TNF-α, and C. cystatin C in different groups in this study (*significance of p value < 0.05). [Figure 8A] Figure 8: 6MWT and NSAA results in different groups of this study (*significance of p value < 0.05). [Figure 8B] Figure 8: 6MWT and NSAA results in different groups of this study (*significance of p value < 0.05). [Figure 9] Illustrative diagram of the vascular smooth muscle dystrophin-centered approach to managing muscular dystrophies. [Figure 10A] FIG. 10A shows the weight of the quadriceps muscle. [Figure 10B] FIG. 10B shows the weight of the gastrocnemius muscle. [Figure 10C] FIG. 10C shows the weight of the extensor digitorum longus. [Figure 11A] FIG. 11A shows plasma ALT. [Figure 11B] FIG. 11B shows plasma AST. [Figure 12] FIG. 12 shows plasma LDH. [Figure 13] Increased LDH in mdx mice reported in the following publication: Murphy S, Dowling P, Zweyer M, Henry M, Meleady P, Mundegar RR, Swandulla D, Ohlendieck K. Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy. Int J Mol Med. 2017 Jun;39(6):1357-1370. doi: 10.3892 / ijmm.2017.2952 [Figure 14] FIG. 14 shows plasma cystatin C. [Figure 15] FIG. 15 shows plasma haptoglobin. [Figure 16] FIG. 16 shows plasma TGF-beta. [Figure 17] FIG. 17 shows plasma IL-13. [Figure 18] FIG. 18 shows representative photomicrographs of HE-stained muscle sections. [Figure 19] FIG. 19 shows representative H&E images. [Figure 20] FIG. 20 shows the reduced inflammation score in N-163. [Figure 21] FIG. 21 shows representative photomicrographs of Sirius Red stained muscle sections. [Figure 22] FIG. 22 shows the fibrotic areas (Sirius red staining). [Figure 23] FIG. 23 shows representative photomicrographs of Masson's trichrome stained muscle sections. [Figure 24]FIG. 24 shows the fibrotic areas (areas positive for Masson's trichrome staining). [Diagram 25] FIG. 25 shows another image of Masson's trichrome staining. [Figure 26] FIG. 26 shows the expansion of Bacteroides after N-163. [Figure 27] FIG. 27 shows that Faecalibacterium prausnitzii was the most abundant species after N-163. [Figure 28] FIG. 28 shows that gut bacteria decreased after N-163 beta-glucan, but increased in the control group. [Figure 29] FIG. 29 shows an increase in Lactobacillus following N-163 beta glucan, but a decrease in the control group. [Diagram 30] FIG. 30 shows that roseburia increased after N-163 beta glucan, but decreased in the control group. [Diagram 31] FIG. 31 shows an increase in Bifidobacteria after N-163 beta glucan, but a decrease in the control group. [Diagram 32] FIG. 32 shows the increase in Prevotella following N-163 beta glucan. [Diagram 33] FIG. 33 shows a decrease in Alistipes following N-163 beta glucan, but an increase in the control group. [Diagram 34] FIG. 34 shows that Firmicutes decreased after N-163 beta-glucan, but increased in the control group. [Diagram 35] FIG. 35 shows the reduction of Akkermansia mucinipihla following N-163 beta glucan. [Diagram 36] FIG. 36 shows the MRC muscle strength grades as percentages. [Figure 37] FIG. 37 shows the mean calcium levels in serum. [Figure 38] FIG. 38 shows the mean CPK in serum. [Figure 39] FIG. 39 shows the mean ALP in serum. [Diagram 40] FIG. 40 shows the decrease in IL-6 following N-163. [Diagram 41] FIG. 41 shows the reduction in C-reactive protein (CRP) following N-163. [Diagram 42] FIG. 42 shows an increase in Bacteroidetes and a decrease in Firmicutes after N-163. [Diagram 43] FIG. 43 shows the expansion of Prevotella after N-163. [Diagram 44] FIG. 44 shows that the abundance of Faecalibacterium prausnitzii increased after N-163 intervention. [Diagram 45] FIG. 45 shows that the abundance of Prevotella copri increased after N-163 intervention. [Diagram 46] FIG. 46 shows that the abundance of Bifidobacterium longum increased after N-163 intervention. [Figure 47] FIG. 47 shows that the abundance of Streptococcus parasanguinis decreased following N-163 intervention. [Figure 48] FIG. 48 shows that the abundance of Streptococcus salivarius decreased after N-163 intervention. [Figure 49] FIG. 49 shows that the abundance of Parabacteroides distasonis increased after N-163 intervention. [Figure 50] FIG. 50 shows that the abundance of Roseburia intestinalis increased following N-163 intervention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] [Detailed Description of the Invention] The glucan used in the present invention may be a glucan derived from Aureobasidium pullulans APNN-M163 strain (also referred to herein as "M163 strain" or "N-163 strain"), and is preferably a β-1,3-1,6 glucan derived from N-163 (also referred to herein simply as "N-163 glucan" or "N-163 beta glucan"). "Aureobasidium pullulans APNN-M163 strain" was deposited on February 9, 2021 at the National Institute of Technology and Evaluation, Patent Microorganisms Deposit Center (Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan 292-0818) under the deposit number NITE P-03377.

[0010] The glucan produced by the N-163 strain was estimated to have the following chemical structure (Japanese Patent Application No. 2021-187255). [ka]

[0011] The composition of the present invention exerts its function when it is ingested by mammals, including humans.As used herein, the term "ingestion" does not limit any administration route, as long as it can enter the human body, and can be achieved by all known administration methods, such as oral administration, tube administration, and enteral administration.Generally, oral intake and enteral intake via the digestive tract are preferred.

[0012] The dosage of the present invention can be appropriately set in consideration of various factors such as administration route, age, body weight, and symptoms. The dosage of the composition of the present invention is not particularly limited, but the amount of glucan is preferably 0.05 mg / kg / day or more, more preferably 0.5 mg / kg / day or more, and particularly preferably 1.0 mg / kg / day. However, when ingested for a long period of time, the amount may be smaller than the above-mentioned preferred amount. Furthermore, the glucan used in the present invention has sufficient dietary experience and is not problematic in terms of safety. Therefore, an amount far exceeding the above-mentioned amount (for example, 10 mg / kg / day or more) is also possible.

[0013] The composition of the present invention can be used as a food or drink. The composition of the present invention can be administered to animals such as humans as a food for specified health uses and a food with nutritional function claims, thereby achieving treatment or prevention of various diseases related to fibrosis.

[0014] When the composition of the present invention is used as food or beverage, the type of food or beverage is not particularly limited.Furthermore, the shape of food or beverage is not particularly limited, and can be any shape of commonly used food or beverage.For example, it can be any shape such as solid shape (including powder and granule shape), paste shape, liquid shape, and suspension shape, and is not limited to these shapes.

[0015] When used as a medicine, the composition of the present invention can reach the intestine, so a dosage form that can be administered orally is preferred.Examples of preferred dosage forms of the drug according to the present invention include tablets, coated tablets, capsules, granules, powders, solutions, syrups, troches, etc. These various preparations are formulated according to conventional methods by using glucan as an active ingredient, excipients, binders, disintegrants, lubricants, colorants, flavorings, solubilizers, suspending agents, coating agents, etc. They can be formulated by mixing auxiliary agents that are commonly used in the technical field of pharmaceutical preparations.

[0016] In some embodiments, the present invention may be used in combination with other foods, beverages, drugs, and any other substances to enhance the efficacy of the present invention.

[0017] In one aspect, the composition or medicament of the present invention may improve the gut microbiota of a subject in need thereof, such as a patient with muscular dystrophy, multiple sclerosis, and / or related diseases, thereby allowing the composition or medicament of the present invention to improve, prevent, and / or treat these diseases.

[0018] In one embodiment, improving the gut microbiota includes, but is not limited to, a reduction in Enterobacteriaceae, an increase in Lactobacillus, an increase in Roseburia, an increase in Bifidobacterium, an increase in Prevotella, a reduction in Alistipes, a reduction in Firmicutes, a reduction in Akkermansia, or a combination thereof, wherein the compositions or medicaments of the present invention may be used to improve, prevent, and / or treat muscular dystrophy, such as Duchenne muscular dystrophy (DMD).

[0019] Gut bacteria have been described to enhance inflammatory responses and therefore their reduction may be beneficial in multiple sclerosis and DMD (reference: https: / / www.mdpi.com / 2076-2607 / 9 / 4 / 697 / htm). Restoration of Lactobacillus species has been shown to reduce inflammatory cytokines, the augmentation of which by N-163 is beneficial in MS (Reference: https: / / www.mdpi.com / 2076-2607 / 9 / 4 / 697 / htm). An increase in Roseburia is a marker of gut health because it is a bacterium that produces butyric acid, a beneficial metabolic product (Reference: Future Microbiol 2017: 157-170). Bifidobacterium longum has been reported to increase muscle function and cognitive skills (Reference: https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC7745561 / ). Therefore, the increase in Bifidobacterium longum after N-163 is beneficial. Alistipes contributes to inflammation and epithelial changes (https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC7745561 / ). Firmicutes play a role in the development of depression by influencing host inflammation levels (https: / / www.frontiersin.org / articles / 10.3389 / fcimb.2022.831186 / ). Increased abundance of Akkermansia has been reported in patients with PD and MS (https: / / pubmed.ncbi.nlm.nih.gov / 28843021 / ). Therefore, a reduction in these bacteria is beneficial.

[0020] In another embodiment, improving the gut microbiota includes, but is not limited to, increasing Bacteridetes, decreasing Firmicutes, increasing Prevotella, increasing Faecalibacterium prausnitzii, increasing Prevotella copri, increasing Bifidobacterium longum, decreasing Streptococcus parasanguinis, decreasing Streptococcus salivarius, increasing Parabacteroides distasonis, increasing Roseburia intestinalis, or combinations thereof, wherein the composition or medicament of the present invention can be used to improve, prevent, and / or treat multiple sclerosis.

[0021] MS patients have presented with gut dysbiosis accompanied by a reduction in bacteria belonging to the genus Prevotella, especially Prevotella copri (https: / / pubmed.ncbi.nlm.nih.gov / 30513004 / ;https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC5730390 / ). The anti-inflammatory resident bacterium Fecalibacterium has been reported to be less abundant in patients with MS (J Investig Med. 2015 Jun;63(5):729-34. doi: 10.1097 / JIM.0000000000000192.). Bifidobacteria have a substantial role in regulating immune responses, and it has been reported that bifidobacteria are less frequent in the gut of MS patients (https: / / www.sciencedirect.com / science / article / abs / pii / S2211034819303554). The abundance of Parabacteroides distasonis is decreased in MS patients (https: / / www.pnas.org / doi / 10.1073 / pnas.1711235114). R. intestinalis has been shown to prevent intestinal inflammation (https: / / www.frontiersin.org / articles / 10.3389 / fcimb.2021.757718 / full). Therefore, an increase in these bacteria after N-163 would be beneficial. Streptococcus parasanguinis (www.pnas.org / cgi / doi / 10.1073 / pnas.2011703117), S. salivarius / thermophilus (www.pnas.org / cgi / doi / 10.1073 / pnas.2011703117) have been reported to be significantly increased in MS patients, so a reduction in these bacteria after N-163 would be beneficial. EXAMPLES

[0022] Example 1 method: This study was an investigator-initiated, single-center, randomized, open-label, prospective, comparative, two-arm clinical study of patients with DMD. The study ran for 45 days. Two treatment arms were included: Treatment arm I, control arm: conventional treatment regimen including standard routine physiotherapy for joint mobility in addition to medication, i.e. T. deflocort (steroid) 6mg-24mg with or without medication, T. calcium and vitamin D1000. Treatment arm II, intervention: conventional treatment plus one packet of N-163 beta-glucan (15 g gel) once daily. Inclusion criteria: Male subjects aged 6–18 years with a molecular diagnosis of DMD who were willing to participate in the study with written informed consent. Exclusion criteria: patients with previous (within the past month) or concurrent participation in any other therapeutic trial; patients with known or suspected malignancy; patients with any other chronic disease or clinically relevant limitations in renal, hepatic, or cardiac function as judged by the investigator.

[0023] investigation: The following tests were performed after written consent was obtained from the study subjects.

[0024] At baseline and end of study (45 days): -Background survey: gender, date of birth, age, habits, current medical history, medication, treatment, allergies (to drugs and foods), regular use of foods for specified health uses, intake of functional foods, health foods, foods rich in beta-glucan foods containing beta-glucan, and intake of foods that boost immunity - Medical history and physical measurements: height, weight, BMI, temperature -Physiological tests: systolic blood pressure, diastolic blood pressure, pulse rate -ECG -Muscle strength testing using MRC grading

[10] - 6-minute walk test (6MWT)

[11] -North Star Ambulatory Assessment (NSAA)

[12] -Blood sampling and investigation of blood levels of IL-6, IL-13, TGF-β, creatine kinase (CK), titin, haptoglobin, TNF-α, dystrophin, cystatin, and urinary myoglobin -Subjects were contacted weekly to record compliance and any adverse effects.

[0025] Study subjects=28 The study was designed as an exploratory study, for which there were two intervention conditions: one control group and one test group. The minimum number of participants required for statistical comparisons within and between intervention conditions was four per intervention condition, so a total of 28 target study participants (10 in the treatment arm I [control] group and 18 in the treatment arm II [N-163] group) were used.

[0026] Selection of research subjects The study investigator and other investigators included subjects who agreed to participate in the study, met the inclusion criteria but not the exclusion criteria, and were deemed comfortable participating in the study.

[0027] Allocation of study subjects The randomizer assigned study subjects to the two groups by simple randomization as specified in the study protocol.

[0028] Primary outcome: - Observation of changes from baseline in IL-6 and myoglobinuria levels.

[0029] Secondary outcomes: - Observation of changes in serum levels of IL-6, IL-13, TGF-β, CK, titin, dystrophin, haptoglobin, cystatin C, and TNF-α, as well as levels of urinary myoglobin measured by ELISA. -Monitoring for adverse effects

[0030] Statistical analysis: All data were analyzed using Excel statistical package analysis software (Microsoft Office Excel®); Student's t-test and ANOVA were used. In cases where there were significant main effects, post-hoc pairwise comparisons were performed and a p-value <0.05 was considered significant.

[0031] result: Twenty-eight patients were screened and 27 were randomized to control (n=9) and treatment (n=18). One patient was disqualified due to an inaccurate description of the diagnosis. The CONSORT flow diagram of the study is shown in Figure 1. Target attributes The mean age ± SD for the entire study population was 11.18 ± 3.86 years (range 5-19 years) and was similar across groups. The mean weight ± SD was 35.59 ± 15.5 kg (range = 10-65 kg).

[0032] [Table 1]

[0033] The distribution of patients was as follows: Group I: control group (n=9); A. No steroid administration (n=5) (steroid-ve) B. Steroid administration (n=4) (steroid +ve) Group II: treatment (N-163) group (n=18); A. No steroid administration (n=9) (steroid-ve) B. Steroid administration (n=9) (steroid +ve)

[0034] No adverse events were reported. No clinically significant changes from baseline data were observed on physical examination or in vital signs (temperature, blood pressure, oxygen saturation, pulse rate, or ECG) (data not shown).

[0035] Biomarker Levels: Levels were expressed as mean ± standard deviation. IL-6 showed the greatest decrease in the N-163 steroid-ve group, from a baseline value of 7.2 ± 1.2 pg / ml to 2.7 ± 0.03 ng / ml after intervention, however the difference was not significant (p value = 0.16) (Figure 2).

[0036] IL-13 increased in both control groups from 300.4±114.5pg / ml at baseline to 550.732±107.95pg / ml at post-intervention in the steroid-ve group and from 142±112.82pg / ml at baseline to 263.5±99.38pg / ml at post-intervention in the steroid+ve group. It decreased in both treatment groups from 157.76±148.68pg / ml at baseline to 114.08±81.5pg / ml at post-intervention and from 289.56±232.88pg / ml at baseline to 255.56±214.13pg / ml at post-intervention. The differences were statistically significant (p-value=0.004) (Figure 3). FIG. 3: IL-13 levels showed a statistically significant increase in the control group but decreased in the treatment group ( * p-value significance <0.05).

[0037] TGF-β levels showed a significant decrease in the N-163 steroid-ve group from a baseline value of 3302 ± 1895 ng / ml to 1325.66 ± 517 ng / ml after intervention, which was significantly lower than all other groups (p value = 0.0001) (Figure 4).

[0038] Dystrophin levels showed a significant increase in the N-163 steroid-ve group from a baseline value of 3.01±1.58ng / ml to 4.01±1.44ng / ml after intervention, and in the N-163 steroid+ve group from a baseline value of 3.15±2.43ng / ml to 3.78±2.17ng / ml after intervention, which was significantly higher than the control group (p-value=0.0009) (Figure 2). The N-163 steroid-ve group showed higher dystrophin expression than the N-163 steroid+ve group, but the difference was not significant (p-value=0.11). The increase in dystrophin levels in the treatment groups was up to 32.8%.

[0039] Haptoglobin showed no significant difference before and after the intervention in the treatment groups, but increased slightly in the control group (Figure 6A). CK increased in the treatment groups (Figure 6B). Urinary myoglobin increased in the N-163 steroid +ve group, but decreased in all other groups (Figure 6C).

[0040] Titin and cystatin C were decreased in the N-163 steroid +ve and control steroid +ve groups, but the differences were not significant (Figure 7A,B). TNF-α was decreased in all groups except the N-163 steroid -ve group. 6MWT and NSAA did not show any significant differences between the groups (Fig. 8A, B). MRC grading showed improvement in 12 of 18 patients (67%) in the treatment group, but only in 4 of 9 subjects (44%) in the control group (Table 2).

[0041] [Table 2]

[0042] Consider: Current interventions for DMD, such as corticosteroids and rehabilitation care, help to extend survival into the 20s or 30s. Corticosteroids are still the mainstay of supportive approaches to slow inflammation and the associated decline in muscle strength and function [4]. However, steroids have their own adverse effects, and prescribing them is based on the risk vs. benefit for a particular patient and their tolerance to the drug. Exon-skipping gene therapy and cell-based strategies to replace mutant DMD genes are under development, but the desired outcome has not yet been achieved. On the other hand, nutritional supplements may be considered a potential strategy to alleviate immune regulation and inflammation, due to their low adverse effects and safety [4]. Improvement of exercise performance and mitochondrial respiration by 1,3-1,6 beta-glucan in a zebrafish model of muscular dystrophy [6] has already been reported.

[0043] In this study, we focused on 1-3,1-6 beta-glucan from the black yeast A. pullulans strain N-163, which has been reported to attenuate inflammation, as evidenced by the reduction of anti-inflammatory markers and the production of beneficial immunomodulatory properties.[6-8] The safety profile of N-163 beta-glucan was confirmed by our results.

[0044] Anti-inflammatory and Anti-fibrotic Outcomes: Circulating IL-6 is chronically elevated in individuals with DMD

[13] , which has been reported to contribute to cognitive impairment associated with DMD. IL-6 blockade has been proposed as a therapeutic approach for DMD

[14] . In this study, IL-6 showed the highest reduction in the N-163 steroid-ve group (Figure 2). IL-6 is an acute inflammatory biomarker (14), while IL-13, a profibrotic biomarker

[15] , was significantly reduced (Figure 3). Along with the TGF-β pathway, it is a major pro-inflammatory and pro-fibrotic cytokine that contributes to the chronic inflammatory response leading to replacement of muscle with scar tissue or fibrosis, resulting in muscle weakness and loss of muscle function

[16] . TGF-β levels also showed a significant reduction in the N-163 steroid-ve group (Figure 4). A 20% restoration of dystrophin expression [17,18] is considered to be the point of efficacy in DMD treatment

[19] , and in both treatment groups in this study, an increase of 32.8% from baseline was found (Figure 5), proving N-163 beta-glucan as an effective agent against DMD. This increase in dystrophin may be due to immune modulation, as evidenced through the regulation of anti-inflammatory and anti-fibrotic markers (IL-6, IL-13, and TGF-β).

[0045] Other biochemical markers of relevance: haptoglobin and urinary myoglobin showed no significant differences, but the increase in urinary myoglobin in the N-163 steroid+ve group deserves more analysis of the underlying mechanisms. The higher activity of steroid-treated individuals may place dystrophin-deficient muscles under greater mechanical stress, predisposing them to further damage of muscle fibers and consequently myoglobinuria

[20] . In the N-163 steroid+ve group, as well as in the control steroid+ve group, titin and cystatin C were decreased, whereas there was an increase in CK, which is paradoxical since titin concentrations have been reported to be significantly correlated with serum CK concentrations

[21] .

[0046] Muscle Strength Assessment: There were three assessments performed blinded by the same physiotherapist at baseline and after the intervention to assess muscle strength and tone. 6MWT and NSAA did not show any significant differences between the groups, but MRC grading showed an improvement in muscle strength in 67% of subjects in the treatment group compared to 44% of subjects in the control group, which is significant. The limitation of being a 45-day study is related to muscle strength and functional assessment, calling for a longer study and follow-up period. However, the improvement in MRC grading at day 45, although small, can again be attributed to the immunomodulatory effect of this disease-modifying supplement. This study shows proof of concept that N-163 beta-glucan can address DMD in three aspects: reduced inflammation as shown by reduced IL-6 and TNF-α, reduced fibrosis as evidenced by reduced TGF-β and IL-13, and more importantly, restoration of dystrophin as evidenced by a 32.8% increase in dystrophin levels. These benefits were maintained regardless of steroid use, which is important because this proven safe food supplement may help DMD patients regardless of steroid status.

[0047] Chronic inflammation is common to the pathogenesis of all muscular dystrophies, and immunomodulatory treatments may benefit patients with various types of muscular dystrophies.

[22] Furthermore, modulating the inflammatory response and inducing immunological tolerance to the new dystrophin expression is essential for the success of dystrophin replacement therapy.

[23] The need for evaluation of muscles and myocardium involved in respiratory function needs to be mentioned here, as they are the cause of death in most DMD patients.[1] Other dystrophinopathies, such as limb-girdle muscular dystrophies (LGMD), do not involve respiratory or myocardial muscles, but inflammatory overaction is a common pathophysiology among types of muscular dystrophies.

[22] If efficacy against DMD is proven, it may be considered to extend the beneficial use of N-163 beta-glucan to other dystrophinopathies, such as LGMD.

[0048] DMD is a rare genetic disease with a maximum life expectancy of only into the 30s, with the majority of sufferers dying in their late 20s to 30s. Life expectancy at birth was just over 20 years for those born before 1970, but gradually increased by 10–15 years for those born in the 1980s and 1990s and diagnosed with DMD. This increase is attributable to better or earlier ventilatory support, steroid use, and cardiac care [24, 25], which are only supportive interventions. Further progress and increased life expectancy are expected with recently approved gene therapy

[26] . Although these gene therapies (such as exon skipping) address the underlying cause by splicing selected exons from pre-mRNA at or adjacent to the mutation site, generating translatable transcripts from the mutant dystrophin gene leading to dystrophin expression [26, 27], they are still hampered by challenges such as delivery of gene editing components throughout the musculature and mitigating possible immune responses

[28] . Thus, what is currently needed is to modulate the immune system and control inflammation and subsequent fibrosis to slow disease progression. The early use of steroids in a regular manner later changed to intermittent use, with regimens varying between centers

[29] ; now new steroids with fewer adverse effects are progressing at various stages towards clinical application

[30] . In this context, the safety of this N-163-produced beta-glucan food supplement without adverse reactions is considered an essential added value. Since targeting inflammatory components (the criterion for selecting this supplement for this study) produced beneficial outcomes, further research into this feature may be worthwhile to extend its application to other neuroinflammatory diseases such as multiple sclerosis. At this point, it is essential to mention the gut microbiome for two reasons; firstly, the association of the microbiome with the severity of neuroinflammatory diseases such as multiple sclerosis

[31] and secondly, the fact that beta-glucan has been reported to produce beneficial remodeling of the gut microbiome in a previous study in children with autism spectrum disorder, a neurodevelopmental disease

[32] .For both multiple sclerosis and DMD, steroids are common to suppress inflammation, but the implications of gut microbiota in DMD are less well reported and deserve further investigation.

[0049] The limitations of this study include the uneven distribution of subjects, and the short follow-up period (only 45 days); the improvement of muscle function over the course of the study showed variability, which may be due to the level of sensitivity to changes in functional assessments during disease progression in the age groups. Among the 27 subjects, two-thirds were ambulatory and the rest were non-ambulatory; the difference in the assessment criteria should be noted, but if non-invasive myograms to accurately measure individual muscles could be performed, it may show comparable quantification among all DMD patients at different stages of disease severity. Furthermore, the comparison of steroid consumption with those who did not consume it or who discontinued steroids after the initial consumption period, as well as the diversity of regimens, should also be considered when interpreting the outcomes. All these aspects call for a need for larger randomized clinical trials of longer duration to validate this supplement as a treatment.

[0050] Example 2 Revisiting the therapeutic management of muscular dystrophies from a dystrophin-centered approach to vascular smooth muscle: Duchenne muscular dystrophy (DMD) has long been believed to result from the absence of dystrophin in the sarcolemma of skeletal and cardiac muscle fibers, causing these muscles to weaken. This absence of dystrophin is caused by mutations in the dystrophin gene [33, 34]. Although the vascular smooth muscle defects associated with DMD are well established, most treatment approaches for DMD have primarily addressed skeletal muscle pathophysiology [33, 34]. The pathophysiology of DMD is thought to be caused by the loss of dystrophin in skeletal and cardiac muscles, which destabilizes a highly organized complex of transmembrane and cytosolic proteins that forms a structural link between the extracellular matrix and the intracellular actin cytoskeleton. Destabilization of this complex leads to increased susceptibility of muscle cells to contraction-induced injury, inflammation, failure of muscle regeneration, and the progressive replacement of muscle by fibrous tissue and fat. Currently available gene replacement and exon skipping therapies have not produced the expected results. Previous academic research has suggested that this is due to a lack of understanding of the exact mechanisms by which skeletal muscle dystrophin deficiency produces the clinical phenotype [33, 34]. Recently, strong evidence has emerged

[36] pointing to a deficiency of dystrophin in vascular smooth muscle, rather than in skeletal or cardiac muscle, as the primary cause of DMD. This dystrophin deficiency in vascular smooth muscle affects nitric oxide (NO) production and vasodilation. Thus, it limits blood supply, thereby resulting in muscle ischemia, injury, and fatigue during exercise, which may lead to fibrosis in the long term

[34] . This new evidence is important for all aspects of DMD, from diagnosis to management. Clinical diagnosis of DMD is based on symptoms, blood markers such as elevated creatine kinase, genetic analysis, and skeletal muscle biopsy for dystrophin assessment

[35] . As the primary pathology has been pointed out to be vascular smooth muscle dystrophin deficiency, a diagnosis based only on skeletal muscle evaluation may be insufficient. In addition, a dystrophin homologue expressed on vascular membranes and not encoded by the dystrophin gene has also been reported

[37] .

[0051] Disease progression in DMD is directly proportional to the activity of the musculature. Vascular smooth muscle is in constant motion with pulsatile blood flow, whereas skeletal muscle is not. This aspect points out that vascular smooth muscle may be a major contributing factor in accelerating disease progression. In contrast to skeletal muscle, vascular muscle can switch to a synthetic and largely non-contractile phenotype in response to other factors such as proinflammatory stimuli, diet, or the development of atherosclerosis

[38] , which also influences the disease phenotype in DMD. This may lead to a faster disease progression with advancing age. There are gender differences in DMD, with women being carriers and men being mainly affected by the disease. These differences may be due to the anti-atherosclerotic effects of estrogen and differences in nitric oxide (NO) synthesis from the vascular endothelium in premenopausal women

[39] . The involvement of vascular smooth muscle dystrophin in the dystrophin-glycoprotein complex (DGC) and its association with anchoring proteins of the complex, such as NO synthase (nNOS), aquaporin-4 (AQP4), and acetylcholine receptors, makes DMD a systemic disease that requires systemic interventions rather than skeletal muscle disease-targeted interventions

[39] . The “functional ischemia” aspect of the disease points out that addressing ischemia is crucial to achieve the expected outcomes of both existing and future effective therapies, rather than muscle fatigue contributing to the disease phenotype

[39] . In addition to the above-mentioned changes in vascular smooth muscle cells and endothelium, muscle stem cells (also known as satellite cells) from DMD mice have also been shown to have a reduced ability to promote angiogenesis. These satellite cells promote the secretion of angiogenesis-promoting vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α (HIF-1α), which promotes angiogenesis under normal conditions. The levels of VEGF and hypoxia-inducible factor-1α (HIF-1α) were found to be significantly decreased in dystrophic satellite cells

[40] . Therefore, restoration of VEGF expression has been implemented as one of the important proangiogenic strategies in DMD.Overexpression of VEGF, direct intramuscular delivery of growth factors, inhibition of the vascular growth factor receptor 1 (VEGFR-1), a negative regulator of angiogenesis, modulation of the NO signaling pathway via either l-arginine and NO donor supplementation, genetic nNOS overexpression, and viral-based gene therapy such as 5-phosphodiesterase (PDE5) are some of the therapies being investigated for promoting angiogenesis in the management of DMD through a vascular smooth muscle-dystrophin-centered approach

[40] .

[0052] Other systemic approaches using PPAR agonists are also being investigated as DMD treatments, primarily anti-fibrotic agents focused on smooth muscle. The rationale behind this is that lipid imbalance leading to atherosclerosis contributes to changes in smooth muscle dystrophin. In addition, peroxisome proliferator-activated receptors (PPARs), which regulate genes involved in development, metabolism, inflammation, and many cellular processes, are also involved in fat deposition in these muscles

[41] . It has been reported that activation of PPARβ / δ and its regulation of utrophin A, which compensates for dystrophin deficiency, improves the DMD phenotype in X-linked muscular dystrophy (mdx) mice

[41] .

[0053] Another factor to be investigated in the systemic implications of smooth muscle dystrophin deficiency is the contribution of the autonomic nervous system to fibrosis from functional ischemia

[38] . In addition, gastrointestinal motility disorders such as delayed gastric emptying, reduced intestinal transit, and chronic constipation, in combination with dystrophin deficiency, may lead to increased NF-κB expression. This may lead to a contractile phenotype in the intestine and reduced smooth muscle function, which has been reported in DMD patients

[41] . All these findings point to another important target for a systemic therapeutic strategy for DMD: the gut microbiome-brain axis. Recent studies have highlighted the importance of gut microbiota and PPAR interactions in skeletal muscle pathology. Treatment of mice with the antibiotic metronidazole led to an increase in Proteobacteria and resulted in skeletal muscle atrophy. In these mice, circadian clock mechanism and PPARγ-related changes in peripheral muscles

[41] were observed, suggesting a possible link between dysbiosis and muscle chronometabolic phenotype.

[0054] Thus, therapeutic strategies that could address some of these smooth muscle and vascular dysfunctions along with dysbiosis could be effective agents or adjuncts to existing therapies. Our recent clinical trial of biological response-modifying glucan (BRMG) in young boys with DMD

[42] noted increased plasma levels of dystrophin derived directly from vascular smooth muscle. This is a step forward in addressing the vascular smooth muscle component of pathophysiology in muscular dystrophies. The study also reported reductions in IL-6 and TGF-β, as well as improvements in muscle strength and the 6-minute walk test. These findings may be attributed to the pleiotropic potential of these BRMG in beneficially modulating lipid metabolism, PPAR agonism, and immune regulation. Further studies are warranted to evaluate the potential of such systemically acting agents from a vascular smooth muscle-centered approach.

[0055] Conclusion: In this clinical study, N-163 beta glucan, with or without steroids, helped to reduce IL-6, TGF-β and IL-13, and increase dystrophin levels, along with improving muscle strength, in subjects with DMD. Therefore, N-163 beta glucan is a safe and effective potential therapeutic disease-modifying adjunct for patients with DMD. Although the described benefits may help slow the progression of this devastating disease, confirmation by longer and larger studies will help establish the routine clinical use of this agent as a disease-modifying agent with the potential to help extend the lifespan of DMD patients. After such validation, extension to other dystrophinopathies such as LGMD may be considered, and further in-depth academic investigations into the gut microbiome and its involvement in neuroinflammatory diseases may shed light on the mechanism of action and lead to further beneficial uses.

[0056] background: Duchenne muscular dystrophy (DMD) is an inherited neuromuscular disorder that results in progressive muscle weakness and early death. Steroids remain the predominant approach for supportive care but have side effects; other targeted and gene therapies are also being developed. As there is limited evidence on the use of disease-modifying nutritional supplements in DMD, this pilot study evaluates the supplementation effect of Aureobasidium pullulans-derived 1,3-1,6 beta-glucan from strain N-163 in young patients with DMD.

[0057] method: Twenty-seven patients with Duchenne muscular dystrophy (DMD), 9 in the control arm (receiving conventional treatment), were enrolled. Patients were divided into groups: those not receiving steroids (steroid-ve) (n=5), those receiving steroids (steroid+ve) (n=4), and 18 in the treatment arm (conventional treatment plus N-163 beta-glucan supplement; N-163 steroid-ve, and N-163 steroid+ve); they participated in the study for 45 days. Assessment of muscle function, disease status, and blood levels of IL-6, IL-13, TGF-β, creatinine kinase (CK), titin, TNF-α, haptoglobin, and dystrophin, and urinary myoglobin were performed at baseline and at the end of the study.

[0058] result: IL-6 showed a significant decrease in the N-163 steroid-ve group from a baseline value of 7.2±1.2pg / ml to 2.7±0.03ng / ml. IL-13 decreased in both treatment groups from 157.76±148.68pg / ml to 114.08±81.5pg / ml (N-163 steroid-ve) and from 289.56±232.88pg / e to 255.56±214.13pg / ml (N-163 steroid+ve). TGF-β levels showed a significant decrease in the N-163 steroid-ve group from a baseline value of 3302±1895ng / ml to 1325.66±517ng / ml after intervention. Dystrophin levels increased by up to 32% in both steroid+ve and -ve groups. Medical Research Council (MRC) grading showed muscle strength improvement in 12 of 18 patients (67%) in the treatment group and 4 of 9 (44%) in the control group.

[0059] Conclusion: Supplementation with N-163 beta-glucan food supplements produced disease-modifying beneficial effects: over 45 days, there was a significant reduction in inflammation and fibrosis markers, an increase in dystrophin, and improved muscle strength in DMD subjects, thus making it a potential adjunctive treatment for DMD after validation. Longer follow-up periods and further studies on the mechanism of action and commonalities with other diseases induced by hyperactive inflammation and / or fibrosis will pave the way for their expanded use in other dystrophinopathies and neuroinflammatory diseases. Trial registration: Clinical Trials Registry of India, CTRI / 2021 / 05 / 033346. Registered on 05 / 05 / 2021.

[0060] Example 3: DMD study in the F30S-mdx mouse model 1. Research purpose To investigate the effects of N-163 beta-glucan on MDX mice. 2. Experimental Design and Treatment Schedule 2.1. Research Group Group 1: 15 normal C57BL / 10SnSlc mice received no treatment until sacrifice. Group 2: Vehicle Fifteen MDX mice were orally administered the vehicle [pure water] at a volume of 10 mL / kg once daily from day 0 to day 45. Group 3: N-163 Beta Glucan Fifteen MDX mice were orally administered vehicle supplemented with N-163 beta-glucan at a dose of 3 mg / kg as API in a volume of 10 mL / kg once daily from day 0 to day 45. 3. At the end of the study, non-fasting blood was collected via the abdominal vena cava using a pre-chilled syringe. After sacrifice, the quadriceps, gastrocnemius, soleus, plantaris, tibialis anterior, extensor digitorum longus, diaphragm, and cardiac muscle were harvested and frozen for analysis.

[0061] result: The results are shown in Figures 10-25. Increased muscle weight in the N-163 group is shown in Figure 10. Decreases in plasma ALT and AST in the N-163 group are shown in Figure 11. Decreases in LDH in the N-163 group are shown in Figure 12. Decreases in cystatin in the N-163 group are shown in Figure 14. Decreases in haptoglobin in the N-163 group are shown in Figure 15. Increases in TGF-beta in the N-163 group are shown in Figure 16. Decreases in IL-13 in the N-163 group are shown in Figure 17. Figure 19 and Table 3 show central core fiber-cell counts and images.

[0062] [Table 3] The percentage of centrally nuclear fibers (CNF), assessed by Masson's trichrome staining, was 0 in the normal group, increased to 80% in the vehicle group, and 76.8% in the N-163 group.

[0063] The reduction in inflammation score in N-163 is shown in Figure 20. The reduction in fibrosis score in N-163 is shown in Figures 21 and 22 (Sirius Red staining). Figures 23 and 24 show that fibrosis is reduced in N-163 (Masson's trichrome staining). In our study, CNFs were increased in mdx mice compared to normal mice due to an increase in necrotic fibers. Since N-163 countered necrosis by decreasing inflammation, and the number of peripheral nucleated fibers increased after N-163, the number of CNFs decreased after N-163, indicating an increase in mature normal dystrophin-positive fibers after N-163 administration. Mdx mice had larger sized cells and increased fibrosis compared to normal mice, whereas after N-163 treatment the cells resembled normal cells and fibrosis was also reduced.

[0064] Consider: Increased lipopolysaccharide leads to chronic inflammation, and treatment with adiponectin (ApN) could provide therapeutic benefits in DMD through insulin sensitivity, fat burning, and anti-inflammatory / antioxidative stress properties. In the present study, supplementation with N-163 BRMG could reduce LDH levels, which would help alleviate chronic inflammation [Am J Pathol. 2017 Jul;187(7):1577-1585.]. A dramatic increase in urinary titin excretion, coinciding with the onset of systemic skeletal muscle damage, has been reported in DMD patients and dystrophin-deficient rodents [Neuromuscul Disord. 2017 Jul;27(7):635-645.]. In the present study, it was noted that after N-163 administration, there was a significant decrease in urinary titin levels, thereby reversing skeletal muscle damage. The inducible plasma marker haptoglobin is an acute phase response protein secreted in association with tissue injury and sterile inflammation and has been reported to be elevated in DMD mice. In the present study, there was a significant decrease in the plasma marker haptoglobin after N-163 administration [Int J Mol Med. 2017 Jun;39(6):1357-1370.]. Although TGF-β has been reported to be involved in fibrosis, this study shows that TGF-β also functions as an anti-inflammatory cytokine, helping to balance between inflammation and fibrosis [Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):975-82.]. In one study, treatment with steroids and vitamin D was shown to decrease IL-13, a profibrotic marker [Cytokine. 2018 Feb; 102:55-61.]. In the current study, N-163BRMG was shown to decrease IL-13. In this study, TGF-β was increased in the N-163 group. The N-163 beta glucan group showed a significant decrease in fibrosis area (Masson's trichrome staining positive area) compared with the vehicle group.The inflammation score and fibrosis area in the N-163 beta-glucan group tended to decrease compared to the vehicle group. In DMD, sporadic dystrophin-positive myofibers, called revertant fibers (RFs), are thought to arise from skeletal muscle progenitor cells and expand clonally with age due to frequent regeneration of necrotic fibers [Sci Rep. 2016 Dec 7;6:38371.]. The nuclei of newly regenerated myofibers are located centrally, while those of mature myofibers are located peripherally. In our study, the increase in necrotic fibers led to an increase in CNFs in mdx mice compared to normal mice. We speculate that N-163 addresses necrosis by reducing inflammation, as well as the number of peripheral nucleated fibers increased after N-163, indicating that the number of CNFs decreased after N-163 and that mature normal dystrophin-positive fibers also increased after N-163 administration. The N-163 group showed a significant decrease in fibrosis area (Masson's trichrome positive area) compared with the vehicle group. The inflammation score and fibrosis area in the N-163 beta glucan group tended to decrease compared with the vehicle group.

[0065] Example 4: F16S DMD-Human Study method: Twenty-seven patients with Duchenne muscular dystrophy (DMD) participated: nine in the control arm (receiving conventional treatment) and 18 in the treatment arm (receiving N-163 beta-glucan supplement along with conventional treatment). They participated in the study for 45 days. Fecal samples were collected at baseline and after 45 days and subjected to whole-genome metagenomic sequencing for gut microbiome analysis.

[0066] result: The results are shown in Figures 26-35. The increase in Bacteroides after N-163 is shown in Figure 26. Figure 27 shows that Faecalibacterium prausnitzii was the most abundant species after N-163. The decrease in Enterobacteriaceae after N-163 beta-glucan, but an increase in the control group, is shown in Figure 28. The increase in Lactobacillus after N-163 beta-glucan, but an increase in the control group, is shown in Figure 29. The increase in Roseburia after N-163 beta-glucan, but an increase in the control group, is shown in Figure 30. The increase in Bifidobacterium after N-163 beta-glucan, but an increase in the control group, is shown in Figure 31. The increase in Prevotella after N-163 beta-glucan is shown in Figure 32. The decrease in Alistipes after N-163 beta-glucan, but an increase in the control group, is shown in Figure 33. The decrease in Firmicutes after N-163 beta glucan, but an increase in the control group, is shown in Figure 34. The decrease in Akkermansia muciniphila after N-163 beta glucan is shown in Figure 35.

[0067] Consider: Gut bacteria have been described to enhance inflammatory responses and therefore their reduction is beneficial in multiple sclerosis and DMD (reference: https: / / www.mdpi.com / 2076-2607 / 9 / 4 / 697 / htm). Restoration of Lactobacillus species has been shown to reduce inflammatory cytokines, the augmentation of which by N-163 is beneficial in MS (Reference: https: / / www.mdpi.com / 2076-2607 / 9 / 4 / 697 / htm). An increase in Roseburia is a marker of gut health because it is a bacterium that produces butyric acid, a beneficial metabolic product (Reference: Future Microbiol 2017: 157-170). Bifidobacterium longum has been reported to increase muscle function and cognitive skills (Reference: https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC7745561 / ). Therefore, the increase in Bifidobacterium longum after N-163 is beneficial. Alistipes contributes to inflammation and epithelial changes (https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC7745561 / ). Firmicutes play a role in the development of depression by influencing host inflammation levels (https: / / www.frontiersin.org / articles / 10.3389 / fcimb.2022.831186 / ). Increased abundance of Akkermansia has been reported in patients with PD and MS (https: / / pubmed.ncbi.nlm.nih.gov / 28843021 / ). Therefore, a reduction in these bacteria is beneficial.

[0068] Example 5: F16S-DMD 6-month human study Long-term DMD studies We conducted a clinical study to evaluate the anti-inflammatory and beneficial effects of N-163 beta-glucan food supplement for 6 months in patients with Duchenne muscular dystrophy (DMD). Patients aged between 3 and 30 years were included in the study. Twenty-six patients have been enrolled and the study is ongoing.

[0069] result: The results are shown in Figure 36. The increase in muscle strength is shown in Figure 36. MRC-Strength increased from an average of 67% to 71% at the two month interim report.

[0070] Consider: Increases in muscle strength were reported during the first 6 months of treatment, followed by a plateau for 2 years, with a slower decline thereafter than in untreated patients with conventional therapies such as steroids, which have side effects. (Cochrane Database Syst Rev. 2008;1:CD003725-CD003725.) In this study, increases in muscle strength were reported after the safe food supplement N-163, after the first 2 months of treatment itself.

[0071] Example 6: F32S LGMD-Human Study LGMD research We conducted a clinical study evaluating the anti-inflammatory and beneficial effects of N-163 food supplement for 60 days in patients with other muscular dystrophies besides DMD. Patients aged between 3 and 70 years were included in the study. Six patients completed the study.

[0072] result: The results are shown in Figures 37 to 39. Decreased calcium in serum is shown in Figure 37. Decreased CPK in serum after N-163 is shown in Figure 38. Decreased ALP in serum after N-163 is shown in Figure 39.

[0073] Consider: Abnormal levels of calcium have been reported in muscular dystrophies (Mareedu et al. Front.Physio. 2021). Elevated CPK levels are indicative of muscle disease. (https: / / emedicine.medscape.com / article / 1259041-workup#:~:text=Early%20in%20the%20disease%20process,elevation%20noted%20in%20Becker%20MD.). LGMD is characterized by elevated ALT, AST and LDH (Dis.Markers 2015;2015:543282). Therefore, a reduction in these markers after N-163 would be beneficial.

[0074] Example 7: F27S Multiple Sclerosis – Human Studies method: An open-label, prospective, non-randomized, non-comparative, single-arm clinical study was conducted to evaluate the effect of β1,3-1,6 glucan (beta-glucan) produced by the N163 strain of Aureobasidium pullulans on immune modulation in patients with multiple sclerosis. Study duration = 2 months. Seven patients completed the study.

[0075] result: The results are shown in Figures 40 and 41. The reduction in IL-6 after N-163 is shown in Figure 40. The reduction in C-reactive protein (CRP) after N-163 is shown in Figure 41.

[0076] Consider: Markers of inflammation, IL-6 and CRP, have been shown to be increased in MS and DMD and promote disease pathogenesis (Biomed Res Int. 2015;2015;891972). Blockade of IL-6 has been reported as a treatment for muscular dystrophies (Ebiomedicine 2015;2(4)). Therefore, reduction of these markers after N-163 would be beneficial.

[0077] Example 8: F27S-Multiple Sclerosis Gut Microbiome Analysis Methodology for fecal microbiota metagenomic sequencing of MS patients: Samples were sequenced using Novaseq V1.5 with a read length of 151 bp. Samples were utilized for whole-genome metagenomic analysis. First, reads were filtered to prevent human DNA contamination. Alignments with the human genome were approximately 0.01%–1.6%. Filtered reads were further used for downstream analysis. Additionally, a de novo assembly was performed using the preprocessed reads to obtain a scaffold. These scaffolds were then used for gene prediction.

[0078] result: The results are shown in Figures 42-50. The increase in Bacteroidetes and the decrease in Firmicutes after N-163 are shown in Figure 42. The increase in Prevotella after N-163 are shown in Figure 43. Figure 44 shows that the abundance of Faecalibacterium prausnitzii increased after N-163 intervention. Figure 45 shows that the abundance of Bifidobacterium longum increased after N-163 intervention. Figure 46 shows that the abundance of Bifidobacterium longum increased after N-163 intervention. Figure 47 shows that the abundance of Streptococcus parasanguinis decreased after N-163 intervention. Figure 48 shows that the abundance of Streptococcus salivarius decreased after N-163 intervention. Figure 49 shows that the abundance of Parabacteroides distasonis increased after N-163 intervention. FIG. 50 shows that the abundance of Roseburia intestinalis increased following N-163 intervention.

[0079] Consider: MS patients present with dysbiosis with a reduction in bacteria belonging to the genus Prevotella, especially Prevotella copri (https: / / pubmed.ncbi.nlm.nih.gov / 30513004 / ;https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC5730390 / ). Faecalibacterium, an anti-inflammatory resident bacterium, has been reported to be less abundant in patients with MS (J Investig Med. 2015 Jun;63(5):729-34. doi: 10.1097 / JIM.0000000000000192.). Bifidobacteria have a substantial role in regulating the immune response, and their frequency has been reported to be lower in the gut of MS patients (https: / / www.sciencedirect.com / science / article / abs / pii / S2211034819303554). In MS patients, the abundance of Parabacteroides distasonis is decreased (https: / / www.pnas.org / doi / 10.1073 / pnas.1711235114). R. intestinalis has been shown to prevent intestinal inflammation (https: / / www.frontiersin.org / articles / 10.3389 / fcimb.2021.757718 / full). Therefore, the increase in these bacteria after N-163 is beneficial. Streptococcus parasanguinis (www.pnas.org / cgi / doi / 10.1073 / pnas.2011703117), S. salivarius / thermophilus (www.pnas.org / cgi / doi / 10.1073 / pnas.2011703117) have been reported to be significantly increased in MS patients, so a reduction in these bacteria after N-163 would be beneficial.

[0080] Modifications and other aspects Various modifications and variations of the described glucan products, compositions and methods, and concepts of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain preferred embodiments, it is understood that the invention as claimed is not intended to be limited to such specific embodiments. Various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art of chemistry, biology, medicine, environmental, cosmetic or food technology, or related fields, are intended to be within the scope of the following claims.

[0081] References: 1. Theadom A, Rodrigues M, Roxburgh R, Balalla S, Higgins C, Bhattacharjee R, Jones K, Krishnamurthi R, Feigin V. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014;43(3-4):259-68. doi: 10.1159 / 000369343. 2. Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Schadelin S, Bieri O, Fischer D. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Trials. 2019 Nov 21;20(1):637. doi: 10.1186 / s13063-019-3740-6. PMID: 31752977; PMCID: PMC6869203. 3. Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, Wakefield LM, Woodcock J. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med. 2015 Aug 5;7(299):299rv4. doi: 10.1126 / scitranslmed.aaa7322. PMID: 26246170; PMCID: PMC5951380. 4. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2004;(2):CD003725. doi: 10.1002 / 14651858 5. https: / / www.niams.nih.gov / newsroom / spotlight-on-research / optimizing-steroid-treatment-duchenne-muscular-dystrophy 6. Licitra R, Marchese M, Brogi L, Fronte B, Pitto L, Santorelli FM. Nutraceutical Screening in a Zebrafish Model of Muscular Dystrophy: Gingerol as a Possible Food Aid. Nutrients. 2021 Mar 19;13(3):998. [ PubMed ] 7. Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham SJK. Immune and metabolic beneficial effects of Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle-aged Japanese men: An exploratory study. withRxiv 2021.08.05.21261640; doi: 10.1101 / 2021.08.05.21261640 8. Ikewaki N, Onaka T, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya VD, Rajmohan M, Vaddi S, Senthilkumar R, Preethy S, Abraham SJK. Beneficial effects of the AFO-202 and N-163 strains of Aureobasidium pullulans produced 1,3-1,6 beta glucans on non-esterified fatty acid levels in obese diabetic KKAy mice: A comparative study.bioRxiv 2021.07.22.453362; doi: 10.1101 / 2021.07.22.453362 9. Ikewaki N, Kurosawa G, Iwasaki M, Preethy S, Dedeepiya VD, Vaddi S, Senthilkumar R, Levy GA, Abraham SJK. Hepatoprotective effects of Aureobasidium pullulans derived Beta 1,3-1,6 biological response modifier glucans in a STAM- animal model of non-alcoholic steatohepatitis. bioRxiv 2021.07.08.451700; doi: 10.1101 / 2021.07.08.451700 10. https: / / mrc.ukri.org / research / facilities-and-resources-for-researchers / mrc-scales / mrc-muscle-scale / 11. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, Atkinson L, Reha A, Hirawat S, Miller LL. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010 Apr;41(4):500-10 12. Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, Manzur A, Muntoni F; North Star Clinical Network for Paediatric Neuromuscular Disease. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int. 2012 Jun;17(2):101-9. doi: 10.1002 / pri.520. 13. Stephenson, K. A., Rae, M. G., & O'Malley, D. (2020). Interleukin-6: A neuro-active cytokine contributing to cognitive impairment in Duchenne muscular dystrophy?. Cytokine, 133, 155134. https: / / doi.org / 10.1016 / j.cyto.2020.155134 14. Mammen AL, Sartorelli V. IL-6 Blockade as a Therapeutic Approach for Duchenne Muscular Dystrophy. EBioMedicine. 2015 Mar 28;2(4):274-5. doi: 10.1016 / j.ebiom.2015.03.018. PMID: 26137566; PMCID: PMC4486189. 15. Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano AL, Munoz-Canoves P. Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle. 2011 May 4;1(1):21. doi: 10.1186 / 2044-5040-1-21. 16. Ceco E, McNally EM. Modifying muscular dystrophy through transforming growth factor-β. FEBS J. 2013 Sep;280(17):4198-209. doi: 10.1111 / febs.12266. Epub 2013 Apr 24. PMID: 23551962; PMCID: PMC3731412. 17. Shimizu-Motohashi Y, Komaki H, Motohashi N, Takeda S, Yokota T, Aoki Y. Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches. J Pers Med. 2019 18. Mendell, J. R., Rodino-Klapac, L., Sahenk, Z., Malik, V., Kaspar, B. K., Walker, C. M., & Clark, K. R. (2012). Gene therapy for muscular dystrophy: lessons learned and path forward. Neuroscience letters, 527(2), 90-99. 19. Wells D. J. (2019). What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?. Journal of muscle research and cell motility, 40(2), 141-150. 20. Awano, H., Matsumoto, M., Nagai, M., Shirakawa, T., Maruyama, N., Iijima, K., Nabeshima, Y. I., & Matsuo, M. (2018). Diagnostic and clinical significance of the titin fragment in urine of Duchenne muscular dystrophy patients. Clinica chimica acta; international journal of clinical chemistry, 476, 111-116. 21. Garrood, P., Eagle, M., Jardine, P. E., Bushby, K., & Straub, V. (2008). Myoglobinuria in boys with Duchenne muscular dystrophy on corticosteroid therapy. Neuromuscular disorders: NMD, 18(1), 71-73. 22. Raimondo TM, Mooney DJ. Anti-inflammatory nanoparticles significantly improve muscle function in a murine model of advanced muscular dystrophy. Sci Adv. 2021 Jun 23;7(26): eabh3693. 23. Thomas GD, Ye J, De Nardi C, Monopoli A, Ongini E, Victor RG. Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy. PLoS One. 2012;7(11): e49350. 24. Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M, Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017 Apr 26;12(1):79 25. Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, Perrouin Verbe B. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013 Sep;56(6):443-54. 26. Duan D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy. Mol Ther. 2018 Oct 3;26(10):2337-2356. 27. Echevarria L, Aupy P, Goyenvalle A. Exon-skipping advances for Duchenne muscular dystrophy. Hum Mol Genet. 2018 Aug 1;27(R2): R163-R172. 28. Dzierlega K, Yokota T. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Gene Ther. 2020 Sep;27(9):407-416. doi: 10.1038 / s41434-020-0156-6. 29. Olson EN. Toward the correction of muscular dystrophy by gene editing. Proc Natl Acad Sci U S A. 2021 Jun 1;118(22): e2004840117. 30. Kourakis S, Timpani CA, Campelj DG, Hafner P, Gueven N, Fischer D, Rybalka E. Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? Orphanet J Rare Dis. 2021 Mar 4;16(1):117. doi: 10.1186 / s13023-021-01758-9. 31. Boziki MK, Kesidou E, Theotokis P, Mentis AA, Karafoulidou E, Melnikov M, Sviridova A, Rogovski V, Boyko A, Grigoriadis N. Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know. Brain Sci. 2020 Apr 14;10(4):234. doi: 10.3390 / brainsci10040234. PMID: 32295236; PMCID: PMC7226078. 32. Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Kandaswamy R, Senthilkumar R, Preethy S, Abraham SJK. Beneficial reconstitution of gut microbiota and control of alpha-synuclein and curli-amyloids-producing enterobacteria, by beta 1,3-1,6 glucans in a clinical pilot study of autism and potentials in neurodegenerative diseases. medRxiv 2021.10.26.21265505; doi: 10.1101 / 2021.10.26.21265505 33. Ito K, Kimura S, Ozasa S, Matsukura M, Ikezawa M, Yoshioka K, Ueno H, Suzuki M, Araki K, Yamamura K, Miwa T, Dickson G, Thomas GD, Miike T. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Hum Mol Genet. 2006 Jul 15;15(14):2266-75. 34. Gajendran N. The root cause of Duchenne muscular dystrophy is the lack of dystrophin in smooth muscle of blood vessels rather than in skeletal muscle per se [version 2; peer review: 3 not approved]. F1000Research 2018, 7:1321. https: / / doi.org / 10.12688 / f1000research.15889.2 [ PMC free article ] [ PubMed ] 35. Verhaart IEC, Johnson A, Thakrar S, Vroom E, De Angelis F, Muntoni F, Aartsma-Rus AM, Niks EH. Muscle biopsies in clinical trials for Duchenne muscular dystrophy - Patients' and caregivers' perspective. Neuromuscular Disorder. 2019 Aug;29(8):576-5 36. Kodippili K, Thorne PK, Laughlin MH, Duan D. Dystrophin deficiency impairs vascular structure and function in the canine model of Duchenne muscular dystrophy. J Pathol. 2021 Aug;254(5):589-605. 37. Augier N, Boucraut J, Leger J, Anoal M, Nicholson LV, Voelkel MA, Leger JJ, Pellissier JF. A homologue of dystrophin is expressed at the blood vessel membrane of DMD and BMD patients: immunological evidence. J Neurol Sci. 1992 Feb;107(2):233-8. 38. Rauch U, Shami A, Zhang F, Carmignac V, Durbeej M, Hultgardh-Nilsson A. Increased neointimal thickening in dystrophin-deficient mdx mice. PLoS One. 2012;7(1): e29904. 39. Guenio et al. The Female mdx Mouse: An Unexpected Vascular Story.Journal of Neurology & Neuromedicine 2016. https: / / doi.org / 10.29245 / 2572.942X / 2016 / 2.1014 40. Podkalicka P, Mucha O, Dulak J, Loboda A. Targeting angiogenesis in Duchenne muscular dystrophy. Cell Mol Life Sci. 2019 Apr;76(8):1507-1528. doi: 10.1007 / s00018-019-03006-7. Epub 2019 Feb 15. PMID: 30770952; PMCID: PMC6439152. 41. Manickam R, Duszka K, Wahli W. PPARs and Microbiota in Skeletal Muscle Health and Wasting. Int J Mol Sci. 2020 Oct 29;21(21):8056. 42. Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Subramanian S, Ikewaki N, Iwasaki M, Senthilkumar R, Preethy S, Abraham S. Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, randomized, comparative clinical study. medRxiv 2021.12.13.21267706; doi: 10.1101 / 2021.12.13.21267706 43. Danielle A. Debruin, Nicola Andreacchio, Erik D. Hanson, Cara A. Timpani, Emma Rybalka, and Alan Hayes, The Effect of Vitamin D Supplementation on Skeletal Muscle in the mdx Mouse Model of Duchenne Muscular Dystrophy, Sports (Basel), 2019 May; 7 (5) 96 44. Gang Han, Caorui Lin, Hanhan Ning, Xianjun Gao, and HaiFang Yin, Long-Term Morpholino Oligomers in Hexose Elicit Long-Lasting Therapeutic Improvements in mdx Mice, Molecular Therapy: Nucleic Acids Vol. 12 September 2018 45. SANDRA MURPHY, PAUL DOWLING, MARGIT ZWEYER, MICHAEL HENRY, PAULA MELEADY, RUSTAM R. MUNDEGAR, DIETER SWANDULLA and KAY OHLENDIECK, Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy, DOI: 10.3892 / ijmm.2017.2952 46. Eiji Wada, Takayuki Hamano, Isao Matsui, Mizuko Yoshida, Yukiko K. Hayashi and Ryoichi Matsuda, Renal involvement in the pathogenesis of mineral and bone disorder in dystrophin-deficient mdx mouse, The Journal of Physiological Sciences volume 69, pages661-671 (2019) 47. Esther Lutgens, Marion Gijbels, Marjan Smook, Peter Heeringa, Philip Gotwals, Victor E. Koteliansky and Mat J.A.P. Daemen, Transforming Growth Factor-β Mediates Balance Between Inflammation and Fibrosis During Plaque Progression, Arteriosclerosis, Thrombosis, and Vascular Biology. 2002; 22:975-982 48. Merryl Rodrigues, Yusuke Echigoya, Rika Maruyama, Kenji Rowel Q. Lim, So-ichiro Fukada & Toshifumi Yokota, Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA / 2 background, Scientific Reports volume 6, Article number: 38371 (2016) 49. Werner Klingler, Karin Jurkat-Rott, Frank Lehmann-Horn and Robert Schleip, The role of fibrosis in Duchenne muscular dystrophy, Acta Myologica, 2012; XXXI: p. 184-195 50. Patricia Pinol-Jurado, Xavier Suarez-Calvet, Esther Fernandez-Simon, Eduard Gallardo, Natalia de la Oliva, Anna Martinez-Muriana, Pedro Gomez-Galvez, Luis M Escudero, Maria Perez-Peiro, Lutz Wollin, Noemi de Luna, Xavier Navarro, Isabel Illa, Jordi Diaz-Manera, Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy, DOI: 10.1038 / s41419-018-0792-6 51. Rebeca Martin, Sylvie S. Miquel, Leandro Benevides, Chantal Bridonneau, Veronique Robert, Sylvie Hudault, Florian Chain, Olivier Berteau, Vasco Azevedo Jean-Marc Chatel, Harry Sokol, Luis Bermudez-Humaran, Muriel Thomas, Philippe Langella, Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic, Frontiers in Microbiology, June 2017, Volume 8, Article 1226 52. Florence Gizard, Anne Fernandez, and Filipe De Vadder, Interactions between gut microbiota and skeletal muscle, doi: 10.1177 / 1178638820980490 53.Valerio Baldelli,Franco Scaldaferri, Lorenza Putignani and Federica Del Chierico, The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases, Microorganisms 2021, 9(4), 697 54. Zohreh Tamanai-Shacoori, Imen Smida, Latifa Bousarghin, Olivier Loreal, Vincent Meuric, Shao Bing Fong, Martine Bonnaure-Mallet, Anne Jolivet-Gougeon, Roseburia spp.: a marker of health?, Future Microbiol. 2017 Feb;12: 157-170 55. Shunjie Bai1, Huili Bai, Detao Li1, Qi Zhong, Jing Xie and Jian-jun Chen, Gut Microbiota-Related Inflammation Factors as a Potential Biomarker for Diagnosing Major Depressive Disorder, Front. Cell. Infect. Microbiol., 15 March 2022 56. Anna Heintz-Buschart, Urvashi Pandey, Tamara Wicke, Friederike Sixel-Doring, Annette Janzen, Elisabeth Sittig-Wiegand, Claudia Trenkwalder, Wolfgang H Oertel, Brit Mollenhauer, Paul Wilmes, The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder, Mov Disord. 2018 Jan;33(1):88-98 57. Satvik Mareedu, Emily D. Million, Dongsheng Duan, and Gopal J. Babu, Abnormal Calcium Handling in Duchenne Muscular Dystrophy: Mechanisms and Potential Therapies, Front. Physiol., 09 April 2021 Sec. Striated Muscle Physiology 58. Twee T Do, et al., Muscular Dystrophy Workup, Medscape, Updated: Jul 01, 2021 59. Yuling Zhu, Huili Zhang, Yiming Sun, Yaqin Li, Langhui Deng, Xingxuan Wen, Huaqiao Wang, Cheng Zhang, Serum Enzyme Profiles Differentiate Five Types of Muscular Dystrophy, Dis Markers. 2015;2015:543282 60. Andrew L. Mammen and Vittorio Sartorelli, IL-6 Blockade as a Therapeutic Approach for Duchenne Muscular Dystrophy, EBioMedicine. 2015 Apr; 2(4): 274-275 61. Oriana Del Rocio Cruz-Guzman, Maricela Rodriguez-Cruz, Rosa Elena Escobar Cedillo, Systemic Inflammation in Duchenne Muscular Dystrophy: Association with Muscle Function and Nutritional Status, Biomed Res Int. 2015;2015:891972 62. https: / / healthmatters.io / understand-blood-test-results / firmicutes 63. Spase Stojanov, Ales Berlec, and Borut Strukelj, The Influence of Probiotics on the Firmicutes / Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease, Microorganisms 2020, 8(11), 1715 64. Ashutosh K Mangalam, Joseph Murray, Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis, Expert Rev Neurother. 2019 Jan;19(1):45-53. 65. Brandi L. Cantarel, Emmanuelle Waubant, Christel Chehoud, Justin Kuczynski, Todd Z. DeSantis, Janet Warrington, Arun Venkatesan, Claire M. Fraser, and Ellen M. Mowry, Gut microbiota in MS: possible influence of immunomodulators, J Investig Med. 2015 Jun; 63(5): 729-734. 66. Harry Sokol, Benedicte Pigneur, Laurie Watterlot, and Philippe Langella, Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients, PNAS, October 28, 2008 vol. 105, no. 43, 16731-1673667. Lixing Zhou, Mingming Zhang, Yuming Wang, Robert Gregory Dorfman, Hang Liu, Ting Yu, Xiaotian Chen, Dehua Tang, Lei Xu, Yuyao Yin, Yida Pan, Qian Zhou, Yihua Zhou, Chenggong Yu, Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17 / Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1, Inflamm Bowel Dis. 2018 Aug 16;24(9):1926-1940. 68. Rebeca Martin, Sylvie S. Miquel, Leandro Benevides, Chantal Bridonneau, Veronique Robert, Sylvie Hudault, Florian Chain, Olivier Berteau, Vasco Azevedo, Jean-Marc Chatel, Harry Sokol, Luis Bermudez-Humaran, Muriel Thomas, Philippe Langella, Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic, Front. Microbiol., 30 June 2017 Sec. Food Microbiology 69. Shailesh K. Shahi, Samantha N. Freedman, and Ashutosh K. Mangalam, Gut microbiome in multiple sclerosis: The players involved and the roles they play, Gut Microbes. 2017; 8(6): 607-615. 70. Mehdi Toghi, Sara Bitarafan, Hosein Delavar Kasmaei, Soudeh Ghafouri-Fard, Bifidobacteria: A probable missing puzzle piece in the pathogenesis of multiple sclerosis, Multiple Sclerosis and Related Disorders, Volume 36, November 2019, 101378 71. Daiki Takewaki, Wataru Suda, Wakiro Sato, Lena Takayasu, Naveen Kumar, Kimitoshi Kimura, Naoko Kaga, Toshiki Mizuno, Sachiko Miyake, Masahira Hattori, and Takashi Yamamura, Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis, 22402-22412, PNAS, September 8, 2020, vol. 117, no. 36 72. Egle Cekanaviciute, Bryan B. Yoo, Tessel F. Runia, Justine W. Debelius, Sneha Singh, Charlotte A. Nelson, Rachel Kanner, Yadira Bencosme, Yun Kyung Lee, Stephen L. Hauser, Elizabeth Crabtree-Hartman, Ilana Katz Sand, Mar Gacias, Yunjiao Zhu, Patrizia Casaccia, Bruce A. C. Cree, Rob Knight, Sarkis K. Mazmanian, and Sergio E. Baranzini, Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models, PNAS, October 3, 2017, vol. 114, no. 40, 10713-10718 73. Kai Nie, Kejia Ma, Weiwei Luo, Zhaohua Shen, Zhenyu Yang, Mengwei Xiao, Ting Tong, Yuanyuan Yang, and Xiaoyan Wang, Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species, Front. Cell. Infect. Microbiol., 22 November 2021, Sec. Bacteria and Host

Claims

1. A composition for ameliorating, preventing, and / or treating muscular dystrophy and / or multiple sclerosis comprising beta-glucan.

2. 2. The composition of claim 1, wherein the beta-glucan comprises beta-glucan produced by Aureobasidium pullulans N-163 (NITE P-03377).

3. The composition according to claim 1 or 2, which is used to ameliorate, prevent and / or treat Duchenne muscular dystrophy.

Citation Information

Patent Citations

  • Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use

    US20090022799A1